Fine control of brain GABA A receptors: GABA A (γ-aminobutyric acid type A) receptors are ligand-gated anion channels that mediate fast inhibitory transmission in the mammalian brain. Han et al. investigated if a protein called SHISA7 was involved in regulating GABA A receptor expression and function (see the Perspective by Rudolph and Moss). SHISA7 was found at GABA-releasing synapses, where it interacted with GABA A receptors, controlled receptor concentration at the synapse, sped up receptor deactivation kinetics, and modulated some behavioral properties of benzodiazepines. SHISA7 thus affects surface expression, gating kinetics, and pharmacology of GABA A receptors in the brain. Science , this issue p. 246 ; see also p. 185
Tonic inhibition mediated by extrasynaptic GABAARs regulates various brain functions. However, the mechanisms that regulate tonic inhibition remain largely unclear. Here, we report distinct actions of GluN2A- and GluN2B-NMDA receptors (NMDARs) on tonic inhibition in hippocampal neurons under basal and high activity conditions. Specifically, overexpression of GluN2B, but not GluN2A, reduces α5-GABAAR surface expression and tonic currents. Additionally, knockout of GluN2A and GluN2B decreases and increases tonic currents, respectively. Mechanistically, GluN2A-NMDARs inhibit and GluN2B-NMDARs promote α5-GABAAR internalization, resulting in increased and decreased surface α5-GABAAR expression, respectively. Furthermore, GluN2A-NMDARs, but not GluN2B-NMDARs, are required for homeostatic potentiation of tonic inhibition induced by prolonged increase of neuronal activity. Last, tonic inhibition decreases during acute seizures, whereas it increases 24 h later, involving GluN2-NMDAR-dependent signaling. Collectively, these data reveal an NMDAR subunit-specific regulation of tonic inhibition in physiological and pathological conditions and provide mechanistic insight into activity-dependent modulation of tonic inhibition.
GABA A receptors (GABA A Rs) mediate the majority of fast inhibitory transmission throughout the brain. Although it is widely known that pore-forming subunits critically determine receptor function, it is unclear whether their single-channel properties are modulated by GABA A R-associated transmembrane proteins. We previously identified Shisa7 as a GABA A R auxiliary subunit that modulates the trafficking, pharmacology, and deactivation properties of these receptors. However, whether Shisa7 also regulates GABA A R single-channel properties has yet to be determined. Here, we performed single-channel recordings of α2β3γ2L GABA A Rs cotransfected with Shisa7 in HEK293T cells and found that while Shisa7 does not change channel slope conductance, it reduced the frequency of receptor openings. Importantly, Shisa7 modulates GABA A R gating by decreasing the duration and open probability within bursts. Through kinetic analysis of individual dwell time components, activation modeling, and macroscopic simulations, we demonstrate that Shisa7 accelerates GABA A R deactivation by governing the time spent between close and open states during gating. Together, our data provide a mechanistic basis for how Shisa7 controls GABA A R gating and reveal for the first time that GABA A R single-channel properties can be modulated by an auxiliary subunit. These findings shed light on processes that shape the temporal dynamics of GABAergic transmission. SIGNIFICANCE STATEMENT Although GABA A receptor (GABA A R) single-channel properties are largely determined by pore-forming subunits, it remains unknown whether they are also controlled by GABA A R-associated transmembrane proteins. Here, we show that Shisa7, a recently identified GABA A R auxiliary subunit, modulates GABA A R activation by altering single-channel burst kinetics. These results reveal that Shisa7 primarily decreases the duration and open probability of receptor burst activity during gating, leading to accelerated GABA A R deactivation. These experiments are the first to assess the gating properties of GABA A Rs in the presence of an auxiliary subunit and provides a kinetic basis for how Shisa7 modifies temporal attributes of GABAergic transmission at the single-channel level.
Anesthetics have long been recognized as essential pharmacological agents for surgical procedures, primarily valued for their ability to induce unconsciousness and provide analgesia. However, emerging research over the past 3 decades has revealed an additional and potentially transformative property of certain anesthetics: their ability to protect the heart against ischemic injury. This comprehensive review examines the cardioprotective effects of both intravenous and volatile anesthetics, with particular focus on propofol, ketamine, isoflurane, and sevoflurane. We analyze the molecular mechanisms underlying their protective actions, including modulation of mitochondrial function, reduction of oxidative stress, and regulation of key survival pathways such as PI3K/Akt/GSK3βand p53 signaling. The review evaluates preclinical evidence from cellular and animal models, as well as clinical studies investigating anesthetic-mediated cardioprotection in cardiac surgery patients. Special attention is given to the phenomenon of anesthetic preconditioning and postconditioning, their comparative efficacy, and the challenges in translating these protective strategies into clinical practice. We also discuss emerging concepts such as the role of microRNAs in mediating anesthetic-induced protection and the potential cardioprotective benefits of anesthetic combinations. Finally, we identify critical gaps in current knowledge and propose future research directions that may enhance the clinical application of anesthetic-mediated cardioprotection.
26 July 2024 in Proceedings of the National Academy of Sciences
Current treatments of anxiety and depressive disorders are plagued by considerable side effects and limited efficacies, underscoring the need for additional molecular targets that can be leveraged to improve medications. Here, we have identified a molecular cascade triggered by chronic stress that exacerbates anxiety- and depressive-like behaviors. Specifically, chronic stress enhances Src kinase activity and tyrosine phosphorylation of calmodulin, which diminishes MyosinVa (MyoVa) interaction with Neuroligin2 (NL2), resulting in decreased inhibitory transmission and heightened anxiety-like behaviors. Importantly, pharmacological inhibition of Src reinstates inhibitory synaptic deficits and effectively reverses heightened anxiety-like behaviors in chronically stressed mice, a process requiring the MyoVa–NL2 interaction. These data demonstrate the reversibility of anxiety- and depressive-like phenotypes at both molecular and behavioral levels and uncover a therapeutic target for anxiety and depressive disorders.